- Atezolizumab contributes to prolonging disease-free time. The efficacy of this treatment was significantly associated with an assessment of the expression of the receptor for programmed death, PD-L1. The immunotherapy trial found that patients responded better the higher the expression, Dr. Maciej Bryl, director of the Wielkopolska Center for Pulmonology and Thoracic Surgery, said in an interview with Medexpress.
Lung cancer is the most common cause of death from malignant tumors in both sexes. Only 15-20 percent of patients are diagnosed in the early stage. Eighty percent are already patients with a poor prognosis. What does early diagnosis give us, and what could make early diagnoses as numerous as possible?
Early diagnosis gives us the possibility of either a permanent cure or a very long disease-free period. The problem is that it is difficult to find patients at this stage. For the most part, these are accidental detections and not routine practice, but efforts are being made to increase the number of patients so diagnosed. Early detection gives us the opportunity to remove the cancer focus and the disease will give the patient peace of mind for years, if not a lifetime.
Early diagnosis today is mostly achieved by putting patients in the highest risk group, those who have smoked for many years, under constant surveillance. This looks a little different than in other screening tests. For example, in mammography, cytology screening for cervical cancer or colonoscopy, one test is a closed result. In the case of lung cancer, largely the essence is patient surveillance. The first examination sometimes results in finding a nodule that requires diagnosis. Over the course of a patient's life, more such nodules appear. The observation is that if we see a lun...